Takeda and KSQ Collaborate to Develop and Commercialize Novel Immuno-Oncology Therapies

 Takeda and KSQ Collaborate to Develop and Commercialize Novel Immuno-Oncology Therapies

Takeda and KSQ Collaborate to Develop and Commercialize Novel Immuno-Oncology Therapies

Shots:

  • KSQ to receive $100M+ as up front and preclinical milestones and up to $400M+/ program in option payment and development & commercialization milestones along with royalties on sales of each approved products
  • The deal includes two KSQ’s previously identified & validated T-cell targets with the potential to introduce two additional targets to the collaboration
  • Takeda will lead to funding for all development & commercialization activities. KSQ to get an option to participate in cost/profit sharing on one of the two products based on the T-cell targets previously identified and validated by KSQ, in the US and retain royalties on all ex-US sales for that product

to­ read full press release/ article | Ref: Businesswire | Image: KSQ Therapeutics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post